Pediatric Study Royalty Fund Would Be Created By Wellstone Amendment
This article was originally published in The Tan Sheet
Executive Summary
Drug companies would be required to set aside a portion of product sales to fund pediatric research for off-patent drugs under an amendment Sen. Paul Wellstone (D-Minn.) will offer to the pediatric exclusivity reauthorization bill when it is considered on the Senate floor.
You may also be interested in...
Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Rep. Tauzin Says
Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated
Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Rep. Tauzin Says
Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated
Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Rep. Tauzin Says
Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated